An advisory board wants to study the rare blood clotting associated with the J&J vaccine before making a decision about how to reinstate the shot
An advisory board wants to study the rare blood clotting associated with the J&J vaccine before making a decision about how to reinstate the shot.
The CDC advisory committee has reviewed details from the six patients, all women between the ages of 18 and 48. Each patient developed the clots within one to three weeks of vaccination; one Virginia woman died, another patient in Nebraska is in critical condition, three more remain in the hospital, and two have been discharged.
At the meeting on Wednesday, a CDC official and a Johnson & Johnson executive added that all of the women were white, and only one was taking hormonal contraceptives, which can potentially cause blood clots. Aran Maree, the chief medical officer for the division of Johnson & Johnson that developed the vaccine, revealed that two additional clotting cases occurred during a clinical trial for the vaccine. Tom Shimabukuro, the head of the CDC’s vaccine safety team, added that the clots were concerning because they were associated with low levels of blood cells involved in clotting, which is abnormal in healthy individuals. “We have a picture where we have clots forming in large [blood] vessels in the presence of low platelets, so it’s kind of a paradox here,” Shimabukuro said. “This is unusual — it usually doesn’t happen.” As the Washington Post notes, that combination “has also been seen, rarely, among people who received vaccine developed by AstraZeneca and University of Oxford.” Several European nations have stopped the rollout of the AstraZeneca candidate due to similar concerns about rare blood clots.Read more: New York Magazine »
Father of 8 was set to get 2nd vaccine dose, but contracted COVID-19 and died
Gordon Ballard, a 65-year-old husband and father of eight, died on May 17, 2021, two weeks after he tested positive for COVID-19.